290 reports of this reaction
1.3% of all CRIZOTINIB reports
#20 most reported adverse reaction
PERIPHERAL SWELLING is the #20 most commonly reported adverse reaction for CRIZOTINIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 290 FDA adverse event reports linking CRIZOTINIB to PERIPHERAL SWELLING. This represents approximately 1.3% of all 22,895 adverse event reports for this drug.
Patients taking CRIZOTINIB who experience peripheral swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PERIPHERAL SWELLING is a less commonly reported adverse event for CRIZOTINIB, but still significant enough to appear in the safety profile.
In addition to peripheral swelling, the following adverse reactions have been reported for CRIZOTINIB:
The following drugs have also been linked to peripheral swelling in FDA adverse event reports:
PERIPHERAL SWELLING has been reported as an adverse event in 290 FDA reports for CRIZOTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PERIPHERAL SWELLING accounts for approximately 1.3% of all adverse event reports for CRIZOTINIB, making it a notable side effect.
If you experience peripheral swelling while taking CRIZOTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.